Radforsk Invest

We are investors. We are entrepreneurs. We build companies.

Radforsk Invest invests in and builds companies that develop groundbreaking treatment methods and tools that will address unmet medical needs. We take a holistic, long-term approach and do not shy away from risk. We focus in particular on immune therapy, radiopharmaceutical treatment and precision medicine.

Radforsk Invest uses an evergreen model. This means that the proceeds from successful business ventures are ploughed into financing and developing new portfolio companies, further investments in the existing portfolio, and projects under the auspices of Radforsk Innovation.

We do things differently. Because we believe in our approach. And because we dare.

So far, we have built companies in the Nordic countries, Europe and the USA. We have been involved in nine stock exchange listings, and we have helped to take a number of products to the global market.

We found and develop biotech companies that develop drugs, treatment methods and tools that do not exist today, and that have the potential to make a real difference for patients. We do so either because we, together with innovative researchers and entrepreneurs, are ahead of the field, or because we take a contrary approach where others dare not tread or lack belief, while we dare to do so.

Minor improvements and candidate drugs that many others develop are not for us. We develop innovative drugs that meet significant medical needs, and we focus on technologies based on new approaches.

Active management

Radforsk Invest exercises active management in all the phases of a company's development, from its establishment to the commercial phase

We take a collaborative approach and bring together world-class, scientific, medical, industrial and commercial experience and expertise, both locally and globally. During the establishment phase, we often take on interim leadership roles while putting together a competent management team and organisation. We are concerned with recruiting the best expertise available, and our portfolio companies recruit people from all over the world.

A comprehensive toolbox The Radforsk model, whereby we, through Radforsk Innovation, are ecosystem builders, ensures that we have good access to ideas, that we stimulate groundbreaking research and, not least, that we make continuous efforts to ensure that Radforsk Invest's portfolio companies have the best possible conditions for development.

Portfolio

Our companies

Radforsk Invest is flexible in its ownership of portfolio companies, and it plays an active ownership role if this adds value for the company in question. We have both sold companies shortly after their formation, which we did in the case of OncoImmunity which was sold to NEC in 2019, and been active owners for more than 20 years, as in the case of Photocure.

To make a difference, we cooperate with exceptional individuals and organisations with high implementation capability and tireless commitment.

237 MNOK allocated to cancer research

So far, Radforsk has allocated NOK 237 million to innovative research projects and Centres of Excellence, which, in turn, have resulted in new ideas and technologies that form the basis for the new start-ups we develop. As part of the model and our close collaboration with researchers, in addition to financial support, we also give extensive advice to projects before companies are formed.

Portfolio

Our companies

We have a broad portfolio of companies developing innovative cancer treatments based on excellent research. Our companies are especially strong within immuno-oncology, photodynamic therapy and radionuclides. We have been part of nine initial public offering, IPOs.

Investments

Not listed

The company vision is to provide novel antibiotic resistance breakers to meet the imminent threat to modern medicine of antimicrobial resistance. AdjuTec's core technology is synthesis of β-lactamase inhibitors that inactivates bacteria resistance enzymes. By taking down bacteria defense they are able to preserve susceptibility of broad-spectrum antibiotics.

Read more
Not listed

ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create highly effective and safe therapeutics. The company's AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.

Read more
Not listed

Ledidi has developed and commercialized a secure and seamless end-to-end software for health research and clinical registries. Their SaaS platform empowers the global health and life science community to collaborate and conduct innovative research in real time, together.

Read more
Not listed

Nextera is accelerating a pipeline of TCR-Like antibody lead candidates with exquisite specificity and unique potency towards disease-specific pHLA targets addressing the unmet demand for safe and improved targeted immunotherapy.

Read more
Listed

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Read more
Not listed

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities.

Read more
Listed

Ultimovacs is a clinical stage biotech company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Read more
Not listed

Zelluna Immunotherapy’s mission is to eliminate solid cancers by unleashing the most powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies.

Read more